Health Condition 1: J82- Pulmonary eosinophilia, not elsewhere classified
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
GlaxoSmithKline Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Patients suffering from severe refractory eosinophilic asthma who have an indication from prescribing physician to start or have already started an add on treatment of mepolizumab by SC administration by patients or caregivers at home or healthcare providers in-clinic using a ready to use prefilled autoinjector
Exclusion criteria
Exclusion criteria: Patients with other conditions that could lead to elevated eosinophils such as Hyper eosinophilic Syndromes including Churg-Strauss Syndrome or Eosinophilic Esophagitis Patients with a known pre existing parasitic infestation within 6 months prior to Visit 1 should be treated appropriately before inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of adverse events (AE), serious adverse events (SAE) and adverse events of special interest (AESI)Timepoint: 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Frequency and incidence of clinically significant asthma exacerbations in the pre and 24-week post-exposure period with mepolizumab treatment. 2. Frequency and incidence of clinically significant asthma exacerbations requiring ED visits and/or hospitalization (24 weeks pre and post-exposure period). Timepoint: 24 weeks | — |
Countries
India
Contacts
Public ContactDr Aanchal Gvalani
GlaxloSmithKline Pharmaceuticals Ltd
Outcome results
None listed